Market report: Biotechs up for third week in a row
Saturday, 27 November, 2010
The S&P/ASX 200 Heathcare Index closed in the black on Friday for the third week in a row, as the wider market slipped for the second week in a row.
It closed the week up two percent to 8665.9 points, while the benchmark S&P/ASX 200 Index fell 31.2 points to 4598.
Biotech performer of the week was Cochlear which managed a gain of eight percent to close the week on $78.75. Things weren’t so bright for the other majors, with ResMed down 47 cents to $32.18, while market leader CSL added just 27 cents to close at $35.00.
Like the broader market, volumes were also thin for biotechs on Friday.
Looking at the best and worst performers, biologics company Circadian technologies fell 8.15 percent to $0.62 while antibody specialists Patrys closed the day down 4.76 percent to $0.10.
Among the stocks heading north, biomarker and diagnostics company Healthlinx gained 6.33 percent to $0.084, while spray-on-skin specialists Avita Medical gained 4.76 percent to close Friday on $0.10.
Anti-inflammatory agent could decrease septic shock mortality
Researchers have discovered a naturally occurring blood protein — a type of...
Less penicillin needed to treat Strep A infection than we thought
It's never been known exactly how much penicillin prevents sore throats — the most...
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
